華東醫藥(000963.SZ):子公司與IMBiologics簽署產品獨家許可協議
格隆匯8月15日丨華東醫藥(000963.SZ)公佈,全資子公司杭州中美華東製藥有限公司與韓國IMBiologicscorp.(簡稱“IMB”)簽訂了產品獨家許可協議。中美華東獲得IMB兩款自身免疫領域的全球創新產品IMB-101及IMB-102在包含中國在內的37個亞洲國家(不含日本,韓國和朝鮮)的獨家許可,包括開發、註冊、生產及商業化權益。中美華東將向IMB支付600萬美元首付款,200萬美元技術轉移里程碑付款,最高不超過3.075億美元的開發、註冊及銷售里程碑付款,以及分級最高兩位數的淨銷售額提成費。
本次引進兩款創新生物藥IMB-101和IMB-102,有望針對性滿足自身免疫疾病患者的臨牀需求,並將進一步擴充公司在自身免疫領域的產品管線,與公司現有產品形成有效協同和迭代,提升公司在自身免疫領域核心競爭力。同時,除已有適應症外,IMB-101和IMB102還具備開發其它潛在自身免疫性疾病的潛力,未來其市場空間有望得到持續拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.